Michael Wilson is a Neurology physician. ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 Owens St
Suite 320
San Francisco, CA 941582334
Telephone
414-353-2069Registry record last updated 3 Sept 2013.
Clinical trials
- The Acceptability and Feasibility of an ED-based, Peer-delivered, Suicide Safety Planning Intervention
Sponsor: University of Arkansas
- Written vs Electronic Safety Planning Study
Sponsor: University of Arkansas
- Computerized Assessment and Referral System Screener for Mental Health Evaluations in the Emergency Setting
Sponsor: University of Arkansas
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20251 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20211 payment
- Genentech, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
58.5%gamma-Aminobutyric Acid-ergic Agonist58.5%Baclofen100%Part D≥14 patientsCancer & immunology
26.8%Other immunosuppressants26.8%Dimethyl Fumarate50%Vumerity50%Part D<11 patientsNervous system
14.6%Central Nervous System Stimulant14.6%Methylphenidate Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
9 NIH research awards on record, funded 1985–2026 per NIH RePORTER. The latest:
- Antigen-directed therapies for autoantibody associated neuroinflammatory diseases.
University of California, San Francisco
FY2026$2,098,085RM1NS138808 - Antigen-directed therapies for autoantibody associated neuroinflammatory diseases.
University of California, San Francisco
FY2025$2,098,085RM1NS138808 - Investigation and Treatment of Undiagnosed Neuroinflammatory Diseases
University of California, San Francisco
FY2025$583,466U01NS120836
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”